^




Show legend
Group by Gene:
Include preclinical:

BTK inhibitor
zanubrutinib
ibrutinib
0
BTK inhibitor
pirtobrutinib
acalabrutinib
orelabrutinib
M7583
rituximab
obinutuzumab
ofatumumab
1
CD20 inhibitor
rituximab-pvvr
rituximab-abbs
rituximab / hyaluronidase
Rixathon (rituximab biosimilar)
rituximab-arrx
venetoclax
2
Bcl2 inhibitor
BGB-11417
venetoclax
gilteritinib
midostaurin
ponatinib
3
Multi-tyrosine kinase inhibitor
nintedanib
cabozantinib tablet
cabozantinib capsule
vandetanib
CD19-targeted CAR-T immunotherapy
brexucabtagene autoleucel
tisagenlecleucel-T
lisocabtagene maraleucel
4
CD19-targeted CAR-T immunotherapy
PBCAR0191
CTX110
AUTO1
pCAR-19B
ISIKOK-19
5
Bcl2 inhibitor, CD20 inhibitor
venetoclax + rituximab
venetoclax + obinutuzumab
6
CD52 inhibitor
alemtuzumab
7
DNA methylation inhibitor
azacitidine
PD1 inhibitor
8
PD1 inhibitor
nivolumab
pembrolizumab
9
PI3Kδ inhibitor
idelalisib
nilotinib
olverembatinib
10
Bcr-abl tyrosine kinase inhibitor
PF-114
SCO - 088
TGRX-678
KF-1601
cyclophosphamide
busulfan
11
Alkylating agent
bendamustine RTD
chlorambucil
ACHM-025
cytarabine
12
DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + clofarabine
cytarabine + fludarabine IV
cytarabine
13
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
bosutinib
14
DNMT inhibitor
decitabine
azacitidine oral
clofarabine
nelarabine
asparagine cytarabine conjugate
15
DNA synthesis inhibitor
fludarabine IV
nedaplatin
temozolomide
thioguanine
16
Bcl2 inhibitor, BTK inhibitor
venetoclax + ibrutinib
IDH1 inhibitor
17
IDH1 inhibitor
ivosidenib
olutasidenib
GSK321
18
CD52 inhibitor, CD20 inhibitor
rituximab + alemtuzumab
cytarabine + etoposide IV
19
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + etoposide IV + mitoxantrone
cytarabine + doxorubicin hydrochloride
20
DNA replication inhibitor
bendamustine
21
PI3Kδ inhibitor, CD20 inhibitor
rituximab + idelalisib
idelalisib + ofatumumab
FLT3 inhibitor
quizartinib
HEC73543
FF-10101
22
FLT3 inhibitor
STI-8591
XY0206
D-65476
BGS-2456
AIU2008
FLT3 inhibitor
bortezomib
23
Proteasome inhibitor
ixazomib
carfilzomib
24
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
25
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
methotrexate
26
CD38 inhibitor
daratumumab
isatuximab-irfc
27
DNMT inhibitor, Cytidine deaminase inhibitor
decitabine / cedazuridine
28
Topoisomerase II inhibitor, DNA cross linking agent
idarubicin hydrochloride
29
PD1 inhibitor, BTK inhibitor
pembrolizumab + nivolumab + ibrutinib
pembrolizumab + ibrutinib
Menin-MLL inhibitor
KO-539
SNDX-5613
30
Menin-MLL inhibitor
DS-1594
BMF-219
VTP-50469
D0060-319
31
Tubulin polymerization inhibitor
vincristine
vincristine liposomal
32
Purinergic receptor P1 agonist
cladribine
33
Protein synthesis inhibitor, Asparagine depleter
recombinant Erwinia asparaginase
34
Protein synthesis inhibitor, CD22-targeted cytotoxin
moxetumomab pasudotox
35
Adenosine deaminase inhibitor
pentostatin
36
SYK inhibitor
GS-9973
GS-9876
37
pan-RAF inhibitor
LY3009120
RG6185
38
PLK4 inhibitor
CFI-400945
MGD006
39
CD3 agonist, CD123 inhibitor
XmAb14045
MGD024
IDH2 inhibitor
40
IDH2 inhibitor
enasidenib
TQB3455
41
c-MET inhibitor
LY2801653
42
AXL inhibitor
BGB324
TP-0903
43
Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + cladribine
cytarabine + cladribine
44
ROR1 inhibitor, BTK inhibitor
ibrutinib + UC-961
45
CD47 inhibitor
GS-4721
46
Purinergic receptor P1 agonist, DNMT inhibitor
decitabine + cladribine
47
ILT-3 inhibitor
IO-202
etoposide IV
48
Topoisomerase II inhibitor
doxorubicin hydrochloride
mitoxantrone
doxorubicin hydrochloride
49
GM-CSF inhibitor
lenzilumab
50
NMT inhibitor
PCLX-001
51
NK cell stimulant
CYNK-001
52
Apoptosis stimulant
arsenic trioxide
pelareorep
53
Immunostimulant
DCP-001
54
Asparagine depleter
eryaspase
55
Alkylating agent, DNA synthesis inhibitor
fludarabine IV + treosulfan
56
DNA topoisomerase inhibitor
L-ANN
57
S1P receptor agonist
KRP-203
58
PDH inhibitor, α-KGDH inhibitor
devimistat
59
Topoisomerase II inhibitor, DNA inhibitor
etoposide oral
60
E-selectin antagonist
APL-106
61
ALK inhibitor
crizotinib
ceritinib
62
MDM2 inhibitor, FLT3 inhibitor
quizartinib + RAIN-32
63
PARP inhibitor
talazoparib
olaparib
64
LSD1 inhibitor
ORY-1001
CPI-482
65
VEGFR inhibitor
axitinib
66
CD19-targeted CAR-T immunotherapy, BTK inhibitor
ibrutinib + lisocabtagene maraleucel
67
CDK19 inhibitor, CDK8 inhibitor
RVU120
68
MLL1 inhibitor
JNJ-6617
69
IKZF1 degrader, IKZF3 degrader, BTK degrader
NX-2127
palbociclib
70
CDK4 inhibitor, CDK6 inhibitor
abemaciclib
ribociclib
71
MDM2 inhibitor
RG7388
HDM201
obinutuzumab + acalabrutinib
ibrutinib + rituximab
72
BTK inhibitor, CD20 inhibitor
ibrutinib + obinutuzumab
ibrutinib + ublituximab-xiiy
ibrutinib + rituximab + obinutuzumab
obinutuzumab + zanubrutinib
73
Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
ABT 263
74
XPO1 inhibitor
selinexor
75
Proteasome inhibitor, CD20 inhibitor
rituximab + bortezomib
76
MDM2 inhibitor, BTK inhibitor
acalabrutinib + KRT-232
77
CCR7 receptor antagonist
CAP-100
78
c-KIT-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor
MGTA-117
79
MYC inhibitor
GT19077
WB100
80
BRAF inhibitor
dabrafenib
81
CD19 inhibitor
YT-19
82
RARα agonist
tamibarotene
83
NEDD8 activating enzyme inhibitor, Bcl2 inhibitor
MLN4924 + ABBV-167
venetoclax + MLN4924
trametinib
PD-0325901
84
MEK inhibitor
selumetinib
PD98059
CI-1040
85
CCR4 receptor antagonist
mogamulizumab-kpkc
86
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
87
CD123-targeted CAR-T immunotherapy
UCART123
ACLX-002
88
Topoisomerase II inhibitor, DNMT inhibitor
etoposide IV + decitabine
89
NEDD8 activating enzyme inhibitor, HDAC inhibitor
MLN4924 + belinostat
90
p53 reactivator
APR-246
91
Galectin inhibitor
OTX-008
92
Bcl2 inhibitor, CD47 inhibitor
venetoclax + GS-4721
93
Bcl2 inhibitor, FLT3 inhibitor
venetoclax + quizartinib
94
CD3 agonist, ROR1 inhibitor
NVG-111
95
Topoisomerase II inhibitor, RNA synthesis inhibitor
dactinomycin
96
CD52 inhibitor, CD123-targeted CAR-T immunotherapy
alemtuzumab + UCART123
97
WEE1 inhibitor
AZD1775
98
Bcl-xL inhibitor
A-1331852
99
BRAF inhibitor, CD20 inhibitor
dabrafenib + rituximab
100
TIM-3 antagonist
MBG453
101
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
102
CTLA4 inhibitor
ipilimumab
103
DNA synthesis inhibitor, DNA-directed DNAP inhibitor, Multi-tyrosine kinase inhibitor
cytarabine + midostaurin
104
CD22-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
105
EGFR inhibitor
EGFR inhibitor
106
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
FCR
7+3 (DAC)
FLAI
DA
BR
iFCG
CDIAG
DCAG
VPD
FLAG-IDA
COG AALL0434
DFCI ALL
GRAALL-2005
PETHEMA ALL-96
USC / MSKCC ALL
107
Chemotherapy
CALGB 8811 Larson
HIA
Linker 4-drug
MRC UKALLXII / ECOG2993
R-CHOP
EPOCH-R
R-CVAD
OFAR
COG AALL0232
IA
VRD
CLAG
CALGB 10403
DAV
PCR
iFCR
ADE
108
T-lymphocyte cell therapy
T-lymphocyte cell therapy
109
Tyrosine kinase inhibitor, Chemotherapy
CVAD + Tyrosine kinase inhibitor
110
CAR-T immunotherapy
CAR-T immunotherapy
111
BET inhibitor, FLT3 inhibitor
FLT3 inhibitor + BET inhibitor
112
Sphingosine kinase inhibitor
Sphingosine kinase inhibitor
113
Tyrosine kinase inhibitor, Bcl2 inhibitor
Bcl2 inhibitor + Tyrosine kinase inhibitor
114
mTOR inhibitor
mTOR inhibitor
sirolimus
115
ATR inhibitor
ATR inhibitor
VE-821
PI3K inhibitor
116
PI3K inhibitor
GDC-0941
BAY 1082439
117
JAK inhibitor
JAK inhibitor
118
MEK inhibitor, FLT3 inhibitor
MEK inhibitor + FLT3 inhibitor
119
LIMK2 inhibitor, FLT3 inhibitor
FLT3 inhibitor + LIMK2 inhibitor
120
DHODH inhibitor
DHODH inhibitor
121
Josephin inhibitor
Josephin inhibitor
122
CD70-targeted CAR-T immunotherapy
CD70-targeted CAR-T immunotherapy
ALLO-316
123
CD7-targeted CAR-T immunotherapy
CD7-targeted CAR-T immunotherapy
124
CD64-targeted CAR-T immunotherapy
CD64-targeted CAR-T immunotherapy
HDAC inhibitor
125
HDAC inhibitor
panobinostat
romidepsin
126
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
dasatinib + nilotinib
127
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, CAR-T immunotherapy, PDGFR β antagonist, EphA2 receptor antagonist
CAR-T immunotherapy + dasatinib
128
Bcl2 inhibitor, Hypomethylating agent
Hypomethylating agent + venetoclax
129
DOT1L inhibitor, Bcl2 inhibitor
DOT1L inhibitor + venetoclax
130
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
131
JAK1 inhibitor, JAK2 inhibitor, LSD1 inhibitor
LSD1 inhibitor + ruxolitinib
132
JAK1 inhibitor, JAK2 inhibitor, T-lymphocyte cell therapy
T-lymphocyte cell therapy + ruxolitinib
133
BTK inhibitor, Chemotherapy
BR + ibrutinib
gemtuzumab ozogamicin
134
CD33-targeted antibody-drug conjugate, DNA replication inhibitor
SGN-CD33A
IMGN779
HAG + azacitidine
135
DNA methylation inhibitor, Chemotherapy
HDA + azacitidine
HIA + azacitidine
136
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
imatinib + nilotinib
137
Multi-tyrosine kinase inhibitor, FLT3 inhibitor
FLT3 inhibitor + gilteritinib
gilteritinib + quizartinib
138
CD19 inhibitor, CD3 agonist
blinatumomab
139
PI3Kδ inhibitor, Chemotherapy
BR + idelalisib
140
PI3Kγ inhibitor, PI3Kδ inhibitor
duvelisib
141
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
rituximab + lenalidomide
142
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
143
PD-L1 inhibitor, Bcr-abl tyrosine kinase inhibitor
PD-L1 inhibitor + nilotinib
144
CD22-targeted antibody-drug conjugate, DNA replication inhibitor
inotuzumab ozogamicin
145
DNA replication inhibitor, CD20 inhibitor
CD20 inhibitor + bendamustine
146
Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor
cytarabine / daunorubicin liposomal formulation
147
CD19 inhibitor, CD3 agonist, CD22-targeted antibody-drug conjugate, DNA replication inhibitor
blinatumomab + inotuzumab ozogamicin
148
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, DNA intercalator
cytarabine + daunorubicin
cytarabine + daunorubicin + mitoxantrone
cytarabine + idarubicin hydrochloride
149
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + idarubicin hydrochloride + fludarabine IV
cytarabine + idarubicin hydrochloride
sorafenib
150
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + gilteritinib
sorafenib
sorafenib + LY3009120
151
BRAF inhibitor, BRAF V600E inhibitor, CD20 inhibitor
vemurafenib + rituximab
vemurafenib + obinutuzumab
152
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, Multi-tyrosine kinase inhibitor, DNA intercalator
cytarabine + midostaurin + daunorubicin
153
Aspartate-ammonia ligase inhibitor, Asparagine depleter
calaspargase pegol-mknl
pegaspargase
154
SMO protein inhibitor, Hedgehog cell-signalling pathway inhibitor
glasdegib
155
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
vincristine + mitoxantrone + pegaspargase
156
CD19 inhibitor, CD3 agonist, CD20 inhibitor
rituximab + blinatumomab
157
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
cytarabine + methotrexate
158
Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor
cyclophosphamide + etoposide oral + nelarabine
cyclophosphamide + etoposide oral + clofarabine
159
THF dehydrogenase inhibitor, Alkylating agent, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
160
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent
clofarabine + idarubicin hydrochloride
161
Topoisomerase II inhibitor, Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + idarubicin hydrochloride + cladribine
162
PRPP amidotransferase inhibitor, DNA synthesis inhibitor
mercaptopurine
163
Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA inhibitor
ifosfamide + etoposide oral + mitoxantrone
164
Topoisomerase II inhibitor, Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + mitoxantrone + cladribine
165
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
vincristine + daunorubicin + pegaspargase
166
Topoisomerase II inhibitor, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
vincristine + daunorubicin + pegaspargase + nelarabine
167
THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + methotrexate + idarubicin hydrochloride
168
MCL1 inhibitor, Protein synthesis inhibitor, MYC inhibitor, Apoptosis stimulant, G1-S-specific cyclin-D1 inhibitor
omacetaxine mepesuccinate
169
IDH1 inhibitor, Bcl2 inhibitor
venetoclax + ivosidenib
170
Tubulin polymerization inhibitor, Tyrosine kinase inhibitor
Tyrosine kinase inhibitor + vincristine
171
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
172
PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002
venetoclax + gilteritinib
173
Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + ponatinib
venetoclax + midostaurin
174
CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + blinatumomab
175
DNA methylation inhibitor, Bcl2 inhibitor
venetoclax + azacitidine
176
JAK1 inhibitor, JAK2 inhibitor, Bcl2 inhibitor
venetoclax + ruxolitinib
177
MDM2 inhibitor, Bcl2 inhibitor
venetoclax + RG7388
178
IDH2 inhibitor, Bcl2 inhibitor
venetoclax + enasidenib
179
STAT5 inhibitor, JAK2 inhibitor, FLT3 inhibitor
CEP-701
180
CDK4 inhibitor, CDK6 inhibitor, Bcl2 inhibitor
venetoclax + palbociclib
181
CD19 inhibitor, CD3 agonist, Multi-tyrosine kinase inhibitor
ponatinib + blinatumomab
182
Myeloid kinome inhibitor, SYK inhibitor, FLT3 inhibitor
HM43239
183
DNMT inhibitor, DNA synthesis inhibitor
decitabine + clofarabine
184
SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
RP6530
venetoclax + SNDX-5613
185
Menin-MLL inhibitor, Bcl2 inhibitor
venetoclax + DS-1594
venetoclax + KO-539
186
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + gemtuzumab ozogamicin
187
Chk2 inhibitor, FLT3 inhibitor
PHI-101
188
SYK inhibitor, CD20 inhibitor
obinutuzumab + GS-9973
189
STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
asciminib
nilotinib + asciminib
190
Casein kinase I epsilon inhibitor, PI3Kδ inhibitor, CD20 inhibitor
umbralisib + ublituximab-xiiy
191
BET inhibitor, Bcl2 inhibitor
venetoclax + ABBV 075
venetoclax + ABBV-744
192
CD3 agonist, CD20 inhibitor
epcoritamab-bysp
193
IRAK-4 inhibitor, FLT3 inhibitor
CA-4948
HPB-092
194
TRAIL R2 agonist, Bcl2 inhibitor, TRAIL R1 agonist
venetoclax + ABBV-621
195
DNMT inhibitor, Cytidine deaminase inhibitor, Bcl2 inhibitor
venetoclax + decitabine / cedazuridine
196
Bcl2 inhibitor, BTK inhibitor, CD20 inhibitor
venetoclax + ibrutinib + obinutuzumab
venetoclax + obinutuzumab + acalabrutinib
197
BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
OTX015
198
CD33-targeted antibody- radioimmunoconjugate, α radiation emission
lintuzumab-Ac225
199
CD123-targeted antibody-drug conjugate, DNA replication inhibitor
IMGN632
SGN-CD123A
200
CSF-1R inhibitor, c-KIT inhibitor, FLT3 inhibitor, AKT inhibitor, FMS kinase inhibitor
pexidartinib
201
Lymphoid kinome inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
CG-806
202
TNFα inhibitor, CD19 inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide + tafasitamab-cxix
203
PIM inhibitor, FLT3 inhibitor
MEN1703
quizartinib + AZD1208
204
PI3Kγ inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
venetoclax + duvelisib
205
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, Bcl2 inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
venetoclax + chidamide
206
Topoisomerase II inhibitor, HDAC inhibitor, Proteasome inhibitor
bortezomib + vorinostat + mitoxantrone
venetoclax + olverembatinib
207
Bcr-abl tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + nilotinib
olverembatinib + APG-2575
208
CD45-targeted antibody- radioimmunoconjugate conjugate, α radiation emission
I-131-apamistamab
209
CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist
blinatumomab + olverembatinib
210
STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + asciminib
211
CD19 inhibitor, CD3 agonist, PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab + blinatumomab
212
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor, Apoptosis stimulant, Ribonucleotide reductase inhibitor
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea
213
Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor
venetoclax + flumatinib
214
VEGFR inhibitor, PDGFR inhibitor, BRD3 inhibitor, BRD4 inhibitor, c-KIT inhibitor, Bcl2 inhibitor, BRD2 inhibitor
venetoclax + sunitinib + I-BET151
215
MCL1 inhibitor, Protein synthesis inhibitor, Proteasome inhibitor, DNA synthesis inhibitor, MYC inhibitor, DNA-directed DNAP inhibitor, Apoptosis stimulant, G1-S-specific cyclin-D1 inhibitor
cytarabine + bortezomib + omacetaxine mepesuccinate
216
CD38 inhibitor, Bcl2 inhibitor
venetoclax + daratumumab
217
RARα agonist, DNA methylation inhibitor
azacitidine + tamibarotene
218
TNFα inhibitor, IL-12 inhibitor, DNA methylation inhibitor, IL-6 inhibitor
lenalidomide + azacitidine
219
IDH2 inhibitor, DNMT inhibitor, Cytidine deaminase inhibitor, Bcl2 inhibitor
venetoclax + enasidenib + decitabine / cedazuridine
220
Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
flumatinib
221
Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + cytarabine / daunorubicin liposomal formulation
222
CDK9 inhibitor, Casein kinase 1 alpha inhibitor, p53 stimulant, CDK7 inhibitor
BTX-A51
223
Topoisomerase II inhibitor, DNMT inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + decitabine + mitoxantrone
224
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, PARP inhibitor
talazoparib + gemtuzumab ozogamicin
225
Retinoic acid receptor agonist, Telomerase inhibitor, Cytotoxic T lymphocyte stimulant, Apoptosis stimulant
tretinoin + arsenic trioxide
226
Chk1 inhibitor, Chk2 inhibitor
ACR-368
227
CD123-targeted antibody-drug conjugate, DNA replication inhibitor, Bcl2 inhibitor
venetoclax + IMGN632
228
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor
tagraxofusp-erzs
229
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor, Bcl2 inhibitor
venetoclax + tagraxofusp-erzs
230
p53 reactivator, Bcl2 inhibitor
venetoclax + APR-246
231
CD33-targeted antibody- radioimmunoconjugate, α radiation emission, Bcl2 inhibitor
venetoclax + lintuzumab-Ac225
232
HDAC inhibitor, DNMT inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + decitabine + vorinostat
233
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
234
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
venetoclax + dasatinib
235
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, Bcl2 inhibitor
venetoclax + bosutinib
236
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + sorafenib
237
pan-RAF inhibitor, PDGFR β inhibitor, PDGFR α inhibitor, Multi-tyrosine kinase inhibitor, FLT3 inhibitor
sorafenib + ARO-002
238
PDGFR β inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002 + cytarabine / daunorubicin liposomal formulation
239
PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
avapritinib
240
Bcr-abl tyrosine kinase inhibitor, CD22-targeted antibody-drug conjugate, DNA replication inhibitor, Src kinase inhibitor
bosutinib + inotuzumab ozogamicin
241
CD30-targeted antibody-drug conjugate, Microtubule inhibitor
brentuximab vedotin
242
VEGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + axitinib
243
PI3K inhibitor, mTOR inhibitor
RTB101
244
Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor, Bcl2 inhibitor
paclitaxel + cytarabine + idarubicin hydrochloride
245
STAMP inhibitor, PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib + asciminib
246
CD19 inhibitor, CD3 agonist, PD1 inhibitor
nivolumab + blinatumomab
247
LRRK2 inhibitor, ALK inhibitor
TAE-684
248
ALK inhibitor, EGFR inhibitor
brigatinib
249
AKT inhibitor, p70S6K inhibitor
CCT128930
250
HDAC inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, DNA methylation inhibitor
cytarabine + azacitidine + panobinostat
251
VEGFR-2 inhibitor, c-MET inhibitor
GSK1363089
252
HDAC inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor, CSF-1R inhibitor, JAK2 inhibitor, FLT3 inhibitor
SB939 + pacritinib
253
Menin-MLL inhibitor, LSD1 inhibitor
SNDX-5613 + ORY-1001
254
Glutaminase inhibitor
CB-839
255
Electron transport complex I inhibitor
IACS-010759
venetoclax + AZD5991
256
MCL1 inhibitor, Bcl2 inhibitor
venetoclax + AMG 176
S63845 + S55746
257
CBP inhibitor, EP300 inhibitor
CCS1477
258
MERTK inhibitor, AXL inhibitor, Bcl2 inhibitor
venetoclax + ONO-7475
259
PLK1 inhibitor, Bcl2 inhibitor
venetoclax + NBL-001
260
JAK inhibitor, SYK inhibitor
ALXN2075
261
HER2 inhibitor
trastuzumab
262
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + imatinib
dasatinib + imatinib + nilotinib
263
FGFR inhibitor
pemigatinib
264
Hepatocyte growth factor inhibitor, Trk inhibitor, TrkA receptor antagonist, PKC inhibitor
K-252a
265
VEGFR inhibitor, STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
axitinib + asciminib
266
VEGFR-2 inhibitor, c-KIT inhibitor, FLT3 inhibitor
SU5614
JQ-1
267
BET inhibitor
CPI-0610
ABBV-744
268
DOT1L inhibitor
EPZ-5676
EPZ004777
269
JAK2 inhibitor
CHZ868
270
Bcl2 inhibitor, PARP inhibitor
venetoclax + olaparib
271
CSF-1R inhibitor, FMS kinase inhibitor
OPN-7486
272
PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
MLN518
273
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
274
MCL1 inhibitor
AZD5991
S63845
275
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
chidamide
276
Ubiquitin pathway modulator, GSPT1 degrader
CC-90009
277
DNA PK inhibitor
M3814
278
Autophagy inhibitor, FLT3 inhibitor
quizartinib + Lys05
279
Tyrosine kinase inhibitor, PDGFR α inhibitor, c-KIT inhibitor, FLT3 inhibitor
AG-1296
280
Casein kinase I epsilon inhibitor, PI3Kδ inhibitor
umbralisib
281
Nucleophosmin inhibitor
NSC348884
282
CXCR4 antagonist, FLT3 inhibitor
quizartinib + LY2510924
283
PD-L1 inhibitor
avelumab
284
RAS inhibitor, Vav3 inhibitor
IODVA1
285
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, JNK inhibitor
dasatinib + JNK-IN-8
286
pan-CLK inhibitor
SM09419
CTX-712
287
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, BTK inhibitor, AKT inhibitor, HDAC3 inhibitor
ibrutinib + chidamide
288
DNMT inhibitor, BTK inhibitor
ibrutinib + decitabine
289
Nerve growth factor inhibitor
DR6MP
290
BET inhibitor, BRD4 inhibitor, MYC inhibitor
PLX51107
291
BET inhibitor, BRD4 inhibitor, MYC inhibitor, FLT3 inhibitor
quizartinib + PLX51107
292
Bcl2 antagonist
ABT-737
293
Aurora kinase A inhibitor
MLN8237
294
HDAC inhibitor, PI3K inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + CUDC-907
ponatinib + CUDC-907
295
Mesothelin-targeted antibody-drug conjugate, Microtubule inhibitor
BAY 94-9343
296
ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
MK-2140
297
Menin-MLL inhibitor, FLT3 inhibitor
quizartinib + MI-503
298
PDGFR β inhibitor, Menin-MLL inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002 + MI-503
299
Telomerase inhibitor
BIBR1532
300
MEK inhibitor, SYK inhibitor
selumetinib + GS-9973
301
Menin-MLL inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + MI-503
ponatinib + MI-503
302
Electron transport complex I inhibitor, Bcl2 inhibitor
venetoclax + IACS-010759
303
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, FLT3 inhibitor
quizartinib + IMGN779
304
pan-CLK inhibitor, Bcl2 inhibitor
venetoclax + SM09419
305
B7-H3-targeted CAR-T immunotherapy
s
306
Bcl2 inhibitor, CD70 inhibitor
venetoclax + ARGX-110
307
BMI1 inhibitor, MEK inhibitor
trametinib + BMIi-1
308
MCL1 inhibitor, BMI1 inhibitor
S63845 + BMIi-1
aminoxyrone
309
HSP90 inhibitor
LAM 003
ADX-1612
310
PDGFR β inhibitor, PDGFR α inhibitor, USP10 inhibitor, FLT3 inhibitor
ARO-002 + Wu-5
311
PP2A inhibitor
DT-061
312
STAT3 inhibitor, Insulin receptor substrate protein inhibitor
NT-157
313
Hedgehog cell-signalling pathway inhibitor
GANT61
314
STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + asciminib
315
MELK inhibitor
OTS167
316
SYK inhibitor, FLT3 inhibitor
CB-659
317
Topoisomerase II inhibitor, DNA intercalator
daunorubicin
318
Topoisomerase II inhibitor, ROR1-targeted antibody-drug conjugate
VLS-211
319
CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
DSP-2033
320
LSD1 inhibitor, Bcl2 inhibitor
venetoclax + INCB59872
venetoclax + MK-3543
321
Annexin A1 inhibitor
MDX-124
322
XPO1 inhibitor, Bcl2 inhibitor
venetoclax + selinexor
323
mTOR inhibitor, γ-secretase inhibitor
sirolimus + MRK003
324
RAS inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + RMC-7977
325
MCL1 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + AMG 176
326
NF-κB inhibitor
DC-1-192
327
mTORC1 inhibitor
nanoparticle albumin-bound rapamycin
328
HDAC inhibitor, PI3K inhibitor
CUDC-907
329
CK1α degrader
PIN-A1
330
AXL inhibitor, FLT3 inhibitor
JRF104
331
FLT3 inhibitor, ERN1 inhibitor
quizartinib + STF-083010
332
ERN1 inhibitor
STF-083010
333
TTK inhibitor
S81694
334
TTK inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib + nilotinib + S81694
335
Jumonji H3K27 demethylase inhibitor
GSKJ4
336
PI3Kδ inhibitor, BTK inhibitor
ibrutinib + idelalisib
337
Topoisomerase I inhibitor
irinotecan
338
FGFR inhibitor, HSP90 inhibitor
infigratinib + ADX-1612
339
PI3K inhibitor, mTOR inhibitor, FLT3 inhibitor
quizartinib + PF-04691502
340
CXCR4 antagonist, pan-RAF inhibitor, E-selectin inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + GMI-1359
341
AMPK inhibitor
Compound C
342
Phospholipase A2 inhibitor, Immunomodulator
hydroxychloroquine
343
ULK1 inhibitor, ULK2 inhibitor
MRT68921
344
ITK inhibitor, BTK inhibitor
SNS-062
345
Bcl2 inhibitor, MELK inhibitor
venetoclax + OTS167
346
IDH2 inhibitor, IDH1 inhibitor, Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + midostaurin + LY3410738
347
FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
TKI258
348
THF dehydrogenase inhibitor
pralatrexate
349
CXCR4 antagonist, E-selectin inhibitor, FLT3 inhibitor
quizartinib + GMI-1359
350
PIM inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + AZD1208
351
XPO1 inhibitor, Nuclear export inhibitor
KPT-8602
352
CDK4 inhibitor, Menin-MLL inhibitor, CDK6 inhibitor
abemaciclib + KO-539
353
BRD3 inhibitor, BRD4 inhibitor, Menin-MLL inhibitor, BRD2 inhibitor
KO-539 + OTX015
354
CD33-targeted antibody-drug conjugate, CD7-targeted antibody-drug conjugate, Microtubule inhibitor
BVX001
355
Ubiquitin pathway modulator, FLT3 inhibitor, GSPT1 degrader
quizartinib + CC-90009
356
CD19 inhibitor, CD16A inhibitor, IL-15R stimulant
FT596
357
DNMT inhibitor, Bcl2 inhibitor, FLT3 inhibitor
FLT3 inhibitor + venetoclax + decitabine
358
IL-7R antagonist
OSE-127
359
Purinergic receptor P1 agonist, CD20 inhibitor
rituximab + cladribine
360
Bcr-abl tyrosine kinase inhibitor, MDM2 inhibitor
olverembatinib + APG-115
361
ACVR1 inhibitor, Bcl2 inhibitor, TGF-β RI antagonist
venetoclax + TP-0184
362
ACVR1 inhibitor, TGF-β RI antagonist
TP-0184
363
Microtubule inhibitor, CD74-targeted antibody-drug conjugate
STRO-001
364
Estrogen receptor antagonist
tamoxifen
365
eIF4G1 inhibitor, Bcr-abl tyrosine kinase inhibitor, NF-κB inhibitor, mTORC1 inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, AKT inhibitor
dasatinib + SBI-756
366
KIF11 inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + SB-715992
cabozantinib tablet + SB-715992
367
Electron transport complex I inhibitor, FLT3 inhibitor
quizartinib + IACS-010759
368
MEK inhibitor, Bcl2 inhibitor
venetoclax + trametinib
369
HSP90 inhibitor, HDAC inhibitor
vorinostat + BMS-722782
370
JAK inhibitor, HDAC inhibitor, SYK inhibitor
vorinostat + ALXN2075
371
Thymidylate synthase inhibitor
5-fluorouracil
372
p53 stimulant
thioureidobutyronitrile
373
CD33 inhibitor, CD3 agonist
AMV564
374
pan-RAF inhibitor, DDR inhibitor
PHI-501
375
Mitochondrial OXHPHOS inhibitor, mTOR inhibitor
ME-344
376
Folate receptor 1-targeted small molecule-drug conjugate, Topoisomerase I inhibitor
ELU001
377
PTPN11 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + ERAS-601
gilteritinib + SHP099
378
CDK9 inhibitor, FLT3 inhibitor
CDDD11-8
379
PIM inhibitor, STAT5 inhibitor, RPS6 inhibitor, STAT3 inhibitor, IKKe inhibitor, NF-κB inhibitor, mTOR inhibitor, JAK2 inhibitor, SYK inhibitor, FLT3 inhibitor, AKT inhibitor
EC-70124
380
5T4-targeted CAR-T immunotherapy
OXB302
381
RAC1 inhibitor
NSC23766
382
Nicotinamide phosphoribosyltransferase inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + GMX1778
383
P21-activated kinase inhibitor
FRAX597 + PF-3758309
384
CD123-targeted antibody-drug conjugate, KIF11 inhibitor
VIP943
385
CD9 inhibitor
KBA1412
386
CDK9 inhibitor
PRT2527
387
β-catenin inhibitor, Wnt signalling pathway inhibitor, Bcl2 inhibitor
venetoclax + BC2059
388
β-catenin inhibitor, BRD3 inhibitor, BRD4 inhibitor, Wnt signalling pathway inhibitor, BRD2 inhibitor
OTX015 + BC2059
389
USP47 inhibitor, USP7 inhibitor
P22077
390
Survivin inhibitor
PC-002
391
PRMT5 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + PRT811
392
DHODH inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + DUP 785
393
CDK inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + MK-7965
394
TCR modulator, Minor histocompatibility antigen 1 modulator
BSB-1001
395
pan-CLK inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + SM09419
396
RET inhibitor, FLT3 inhibitor
PLD-102
397
MDM2 protein degrader
MX69-114b
398
CD39 inhibitor, CD73 inhibitor
INT-1B3
399
NRF2 inhibitor, BTK inhibitor
ibrutinib + brusatol
400
NRF2 inhibitor
brusatol
401
Menin-MLL inhibitor, MEK inhibitor
selumetinib + SNDX-5613
402
MERTK inhibitor
RGX-019
403
FLT3-targeted antibody-drug conjugate, Multi-tyrosine kinase inhibitor
midostaurin + 20D9-ADC
404
c-KIT-targeted antibody-drug conjugate, Microtubule inhibitor
NN3201
LOP628
405
RNA polymerase 2 inhibitor, CD45-targeted antibody-drug conjugate
CD45-ADC
406
MERTK-targeted antibody-drug conjugate, Microtubule inhibitor
RGX-019-MMAE
407
DNA replication inhibitor, ROR1-targeted antibody-drug conjugate
NBE-002
408
CD123-targeted antibody-drug conjugate, DNA replication inhibitor, FLT3 inhibitor
quizartinib + SGN-CD123A
409
5T4-targeted antibody-drug conjugate, Microtubule inhibitor
PF-06263507
410
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
411
CCR7-targeted antibody-drug conjugate, Microtubule inhibitor
JBH492
412
DNA replication inhibitor, CD19-targeted antibody-drug conjugate
SGN-CD19B
413
FLT3-targeted antibody-drug conjugate, Microtubule inhibitor
AGS62P1
414
CK1α degrader, Multi-tyrosine kinase inhibitor
gilteritinib + PIN-A1
415
Tubulin polymerization promoter
carboplatin
416
AKT inhibitor
MK-2206
417
ClpP agonist, GPR132 agonist
ONC212
418
DHODH inhibitor, ATR inhibitor
M6620 + BAY2402234
419
CDC7 kinase inhibitor
SGR-2921
420
CD123-targeted antibody-drug conjugate
BYON4413
421
Bcr-abl tyrosine kinase inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + TGRX-678
422
pan-RAF inhibitor, MEK1 inhibitor
cobimetinib + RG6185
423
CDK19 inhibitor, Multi-tyrosine kinase inhibitor, CDK8 inhibitor
gilteritinib + RVU120
424
Bcl-xL degrader
DT2216
425
DNMT inhibitor, Bcl2 inhibitor
venetoclax + NTX-301
426
SMARCA4 inhibitor, SMARCA2 inhibitor
FHD-286
427
Menin-MLL inhibitor, SMARCA4 inhibitor, SMARCA2 inhibitor
SNDX-5613 + FHD-286
428
BRD3 inhibitor, BRD4 inhibitor, SMARCA4 inhibitor, SMARCA2 inhibitor, BRD2 inhibitor
OTX015 + FHD-286
429
MLL1 inhibitor, Bcl2 inhibitor
venetoclax + JNJ-6617
430
XPO1 inhibitor, Menin-MLL inhibitor
selinexor + KO-539
431
FGFR2 inhibitor, FGFR1 inhibitor, JAK inhibitor, PDGFR inhibitor, HPK1 inhibitor, FLT3 inhibitor
Max-40279
432
GART inhibitor
T-64
433
Menin-MLL inhibitor, DOT1L inhibitor
VTP-50469 + EPZ-5676
434
WDR5 inhibitor
OICR-9429
435
MEK2 inhibitor, MEK1 inhibitor
U0126
436
JAK3 inhibitor, JAK1 inhibitor, JAK2 inhibitor
tofacitinib
437
HSP90 inhibitor, Bcl2 inhibitor
venetoclax + LAM 003
438
STAT3 inhibitor, Insulin receptor substrate protein inhibitor, IGF-1R inhibitor
ASP7487 + NT-157
439
Topoisomerase II inhibitor, Phospholipase A2 inhibitor, DNA cross linking agent, PDE3 inhibitor
idarubicin hydrochloride + anagrelide
440
Insulin receptor antagonist, IGF-1R inhibitor
GSK 1838705A
441
SF3B1 inhibitor
E7107
442
Proteasome inhibitor, Reactive oxygen species stimulant, Photosensitizer
bortezomib + verteporfin
No biomarker
BCR-ABL1 fusion
BCR-ABL1 T315I
BCR-ABL1 H396R
BCR-ABL1 F486S
BCR-ABL1 L387M
BCR-ABL1 Q252H
BCR-ABL1 L248V
BCR-ABL1 E459K
BCR-ABL1 D276G
BCR-ABL1 E279K
BCR-ABL1 E355G
BCR-ABL1 M388L + BCR-ABL1 M244V
BCR-ABL1 L323P
BCR-ABL1 Y253F
BCR-ABL1 I403V
BCR-ABL1 I403T
BCR-ABL1 S417Y
BCR-ABL1 V289I
BCR-ABL1 V379I
BCR-ABL1 M244V
BCR-ABL1 G250E + BCR-ABL1 F317L
BCR-ABL1 N49S
BCR-ABL1 E255K
BCR-ABL1 H396P
BCR-ABL1 mutation
BCR-ABL1 V289A
BCR-ABL1 Q252H + BCR-ABL1 V299L
BCR-ABL1 M388L
BCR-ABL1 A397P
BCR-ABL1 I432T
BCR-ABL1 T315L
BCR-ABL1 C475V
BCR-ABL1 L387F
BCR-ABL1 Q300R
BCR-ABL1 E98G
BCR-ABL1 E450Q
BCR-ABL1 L364I
BCR-ABL1 E450G
BCR-ABL1 E355G + BCR-ABL1 Q252R
BCR-ABL1 D444G
BCR exon 13-ABL1 exon 3 fusion
BCR-ABL1 D363G
BCR-ABL1 F317C
BCR-ABL1 F359V
BCR-ABL1 F359C
BCR-ABL1 F359I
BCR-ABL1 G250E
BCR-ABL1 F317L
BCR-ABL1 E255V
BCR-ABL1 Y253H + BCR-ABL1 T315I
BCR-ABL1 V299L
BCR-ABL1 F317I
BCR-ABL1 P465S
BCR-ABL1 A337T
BCR-ABL1 M351T
BCR-ABL1 Q255K
BCR-ABL1 S417T
BCR-ABL1 Y253H
BCR-ABL1 F3llL
BCR-ABL1 E292V
BCR-ABL1 E453A
BCR-ABL1 N336S
BCR-ABL1 V229L
BCR-ABL1 F317V
BCR-ABL1 F311I
BCR-ABL1 T315I + ABL1 E255V
BCR-ABL1 T315I + ABL1 E255K
BCR-ABL1 L384M
BCR-ABL1 F317I + ABL1 F317C
BCR-ABL1 F317I + ABL1 F317C + ABL1 F1317L
BCR-ABL1 T315M
BCR-ABL1 F359
BCR-ABL1 G398R
BCR-ABL1 F311V
BCR-ABL1 Q252R
BCR-ABL1 L248R
BCR-ABL1 T315A
TP53 mutation
TP53 wild-type
TP53 mutation + Chr del(17p)
TP53 deletion
TP53 -181_-179delAAA
TP53 mutation + Chr del(11q)
TP53 R248Q
FLT3-TKD mutation
FLT3 mutation
FLT3-ITD mutation
FLT3-ITD mutation + FLT3-TKD mutation
FLT3‐ITD
FLT3 D835H
FLT3 expression
FLT3 D835Y
FLT3 D835
FLT3 I836
FLT3 F691L
FLT3-ITD mutation + FLT3 D835
FLT3 G846S
FLT3 D835G
FLT3 wild-type
FLT3 Y591_V592INSVDFREYE
FLT3 V592_D593INSDFREY
FLT3 E588_Y589INSKYFYVDFRE
FLT3 positive
FLT3 N676K
FLT3 N676T
FLT3 overexpression
FLT3 I687F
FLT3 D698N
FLT3-ITD expression
FLT3 D651G
FLT3 G619C
FLT3 Y842C
FLT3 N676D + FLT3 Y842C
FLT3 D835V
FLT3-ITD mutation + MLL rearrangement
FLT3 D835F
FLT3 F691L + FLT3 D835F
FLT3 F691L + FLT3 D835H
FLT3 G697R
FLT3 N676D
FLT3 Y842H
FLT3 F691L + FLT3 D835V
FLT3 D839G
FLT3 F691L + FLT3 D839G
FLT3 F691L + FLT3 Y842C
FLT3 D835E
FLT3 D835A
FLT3 V592A + FLT3 D835N
FLT3 D835N
MLL rearrangement + FLT3 mutation
FLT3 NPOS + FLT3 D835N
FLT3 840GS
FLT3 A627T
FLT3-ITD mutation + FLT3 D835Y
FLT3-ITD mutation + FLT3 F691L
FLT3 mutation + MLL mutation
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L
FLT3 F691L + FLT3 D835Y
IDH1 mutation
IDH1 R132H
IDH1 R132S
IDH1 R132
IDH1 R132G
IDH1 R132C
IDH1 R132L
IDH1 R132C + IDH1 S280F
JAK2 fusion
JAK2 F694L
JAK2 mutation
JAK2 rearrangement
JAK2 V617F
STRBP-JAK2 fusion
JAK2 amplification
JAK2 R683G
JAK2 R938Q
CD20 positive
CD20 expression
IGH mutation
ABL1 fusion
ABL1 T315I
IGH mutation + Chr del(13q)
ABL1 expression
IGH mutation + Chr del(11q)
ABL1 G250E + ABL1 D276G + ABL1 T315I
ABL1 T315I + ABL1 M351T + ABL1 L387M
IGH mutation + Chr del(8p)
IGH translocation
ABL1 E255K
ABL1 G250E
ABL1 D276G
ABL1 M351T
ABL1 L387M
ABL1 Y253H
ABL1 exon 4 deletion + ABL1 T315I
ABL1 F359V
ABL1 F317L
SH2B3 alteration
NPM1 mutation
CD19 positive
SH2B3 deletion
NPM1 exon 11 mutation
CD19 expression + Chr t(8;21)
NPM1 W288
CD19 positive + Chr t(8;21)
CD19 deletion
NPM1 expression
CD19 expression
EPOR rearrangement
RUNX1-RUNX1T1 fusion
CRLF2 rearrangement + JAK2 fusion
IL7R mutation
CD52 expression
ABL2 fusion
JAK2 mutation + CRLF2 rearrangement
IL7R expression
EPOR amplification
IDH2 mutation
IDH2 R172K
IDH2 R172
IDH2 R140Q
IDH2 R140
KMT2A rearrangement
KMT2A-PTD
KMT2A mutation
KMT2A expression
FLT3‐ITD  + NPM1 mutation
KIT D816V
KIT mutation
KIT positive
NPM1 mutation + FLT3-TKD mutation
FLT3 mutation + NPM1 mutation
FLT3-ITD mutation + NPM1 mutation
Chr t(8;21) + KIT mutation
KIT exon 8 mutation
KIT V560G
KIT N822K
FLT3-ITD F692L + NPM1 mutation
KIT D816H
KIT expression
Chr inv(16)t(16;16) + KIT mutation
SRSF2 mutation
CD123 positive
CD123 overexpression
SRSF2 P95H
CD123 expression
SRSF2 P95L
BRAF V600E
PML-RARA fusion
FLT3‐ITD + WT1 mutation
FLT3‐ITD + DNMT3A mutation
DNMT3A mutation
CD33 positive
CD33 expression
DNMT3A R882H
BRAF V600
FLT3 mutation + DNMT3A mutation
FLT3-ITD mutation + WT1 mutation
DNMT3A R882
PML-RARA T285I
DNMT3A mutation + FLT3-ITD mutation
BRAF mutation
BRAF mutation + RAS mutation
DNMT3A deletion
BIRC3 mutation
MLL-AFF1 fusion
RUNX1 mutation
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation
IGLL5 mutation
EZH2 mutation
BCL2 mutation
TET2 mutation
CSF3R M696T
BCL2 expression
BTK mutation
CSF3R mutation
CD22 positive
BTK C481
TET2 L1231P
TET2 E227
CD22 expression
CD22 overexpression
CSF3R T618I
BTK L528W + BTK C481
BTK C481S
BCL2 N103E
BCL2 N103Y
BCL2 G101V
BTK T474I
BTK C481R + BTK L528W
BCL2 D103Y
Chr del(5q) + Chr amplification(21)(q22) RUNX1
BCL2 overexpression
BTK R665W
BTK C481S + BTK R665W + BTK L845F + BTK S707Y
BTK C481Y
BTK C481R
BCL2 V156N
BCL2 N107_N110dup
CEBPA mutation
SF3B1 mutation
PTPN11 mutation
ETV6-NTRK3 fusion
ATF7IP-PDGFRB fusion
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation
PAX5 fusion
NPM1 mutation + DNMT3A mutation
TCF3-PBX1 fusion
STAT3 D661Y
ATF7IP-PDGFRB translocation
KRAS wild-type
CRLF2 rearrangement
FLT3 mutation + IDH1 mutation
RUNX1-RUNX1T1 fusion + KIT D816
RARA positive
RARA overexpression
DNMT3A mutation + NPM1 mutation
TCF3-PBX1 rearrangement
PAX5 mutation
Chr t(3;9)(p13;q34) FOXP1/ABL1
CRLF2 overexpression
FLT3-ITD mutation + IDH1 mutation
KRAS G12A
FOXP1-ABL1 Fusion
RAI1 Q279fs
RAI1 Q280fs
CELF2 -93_-93insGAGAGA
CELF2 -93_-93delGAGA
STAT3 Y640F
KRAS mutation
KRAS mutation + U2AF1 mutation
SF3B1 K666N
CRLF2 mutation
Chr del(13q) + Chr del(11q) + SF3B1 mutation
KRAS G12D
PHF6 mutation
TTN 10361-5delT
IKZF2 expression
FLT3-ITD mutation + SKI overexpression
NUP98-NSD1 fusion + FLT3-ITD mutation
JAK3 mutation
BCR-ABL1 fusion + SET underexpression
LGALS1 overexpression + LAG3 overexpression
SPINK2 overexpression
EBF1-PDGFRB fusion
Chr inv(16)(p13;q22)/ CBFB-MYH11 fusion
NUP214-ABL1 fusion
CEBPZ rearrangement + FLT3-TKD mutation
CCR7 expresion
FLT3-ITD mutation + RIPK1 expression
PDGFRB fusion
MLL-MLLT1 fusion
NUP98-PRRX1 fusion
FLT3-ITD mutation + IDH2 mutation
ASXL1 mutation
ALK positive
TNFRSF8 expression
CD123 positive + FLT3-ITD mutation
STAT5b-RARA fusion
NRAS mutation
CD74 expression
SETD2 mutation + RUNX1 mutation
CD40 expression
DDX41 mutation
CDKN2A deletion
TMB-L
IDH1 R132H + PTEN C78T
MRD4 negative
FLT3 mutation + NRAS mutation + PTPN11 mutation
P2RY8-CRLF2 fusion
NR1I2 rs3814055
MYD88 L265P + BRAF V600E
FLT3 mutation + PTPN11 mutation
NCOR1-LYN fusion
IDH2 mutation + NPM1 mutation
FIP1L1-PDGFRA rearrangement
KMT2A rearrangement + NPM1 mutation
CD58 expression
IL3RA positive
DNMT3A mutation + IDH mutation
SPI1 deletion
WNT5B expression
U2AF1 mutation
MTHFR underexpression
miR-199a overexpression
FLT3-ITD mutation + MLL fusion + TP53 mutation
SETBP1 expression
miR-451 overexpression
FLT3 A848P + MLL-MLLT3 fusion
miR-146a expression
miR-21 underexpression
WT1 underexpression
PD-L1 underexpression
CXCR4 overexpression
AXL elevation
NPM1 mutation + DNMT3A mutation + KMT2D mutation
HIF1A overexpression
LDHA elevation
BNIP3L elevation
WSB1 expression
PLCG2 mutation
RANBP2-ALK fusion
IKZF1 deletion + PAX5 deletion
ANG elevation
SLFN11 expression
HOXA9 overexpression + MEIS1 overexpression
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation
IDH1 mutation + TP53 mutation
CCR4 positive
IDH2 mutation + TP53 mutation
TFRC expression
SET-NUP214 fusion
CD14 overexpression
KRAS mutation + BCL2A1 overexpression
BCL2A1 expression
PTPN11 mutations + MCL1 overexpression
CLEC7A overexpression
SH3D19 expression
NUP98-HOXD11 fusion + Chr t(2;11)(q31;p15)
STAG2 mutation
BCOR mutation
BCR expression
GNG4 expression
BCL2/BCL2L1 ratio elevation
RET expression
PAK4 deletion
ETS1 expression
BCL2/MCL1 ratio elevation
IL17A rs3819024
MECOM rearrangement
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation
NPM1 mutation + SRSF2 mutation
INPP5D-ABL1 fusion
KMT2A rearrangement + CD19 positive
NAV3 expression
GAS1 expression
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
PCM1-JAK2 fusion
HLF overexpression + FLT3-ITD mutation
ARHGAP20 expression
NUP98 rearrangement
RNF217-AS1 expression
PTGS2 expression
TNFRSF10D expression
LDH-L
PDLIM4 -62_-60TGC
Chr t(3;11) + KMT2A-LARS2 fusion
PTPN22 2135-4delT
IKZF1 mutation
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
NUP98-RARG fusion
CACNA1B N167K
ETV6-FLT3 fusion
TET2 mutation + NRAS mutation
CD19 negative + CD20 negative + CD22 negative
PRDM1 mutation
KAT6A-CREBBP fusion + FLT3-TKD mutation
GOLGA5-JAK2 fusion
LILRB4 overexpression
BRAF mutation + TET2 mutation
MYC amplification
BCR exon 1-PDGFRA exon 13 fusion
KCNJ12 -52C>T
IDH2 mutation + SRSF2 mutation
MAGEE1 expression
CSF1R fusion
MYO16 *170_*179delTTGTGTGTGT
PD-1 overexpression
GLI3 expression
ANO5 *113delT
IKZF3 mutation
TP53 mutation + IKZF1 mutation
TP53 mutation + IKZF3 mutation
ABCB1 3435C>T
HOXA9 overexpression
CD19 positive + CD20 positive
MEIS1 overexpression
PDGFRB C843G
NRAS G12D
WT1 mutation
JAK3 M511I
ASXL1 G646Wfs*12
SLFN11 underexpression
WT1 overexpression
IKZF1 deletion
MYC underexpression
Chr inv(3)t(3;3) + MECOM overexpression
ASXL1 deletion
BCL2A1 overexpression
CCR7 overexpression
ALK A348D
ALK F856S
FIP1L1-PDGFRA fusion
IL3RA expression
PD-L1 overexpression
MYC overexpression
NUP214-ABL1 rearrangement
MYC translocation
FLT3 wild-type + TP53 mutation
IDH2 R140Q + NPM1 mutation
MYC expression
CD14 expression
Chr del(17p)
CBFB-MYH11 fusion
Chr del(13q)
MLL rearrangement
Chr del(11)(q22.3)
Chr t(4;9;22)(q21;q34;q11)
Chr del(11q)
Chr t(1;16)(q12;q11.2)
Chr del(17)(p13.1)
RAS mutation
Chr t(15;17)
Chr del(5q)
MLL rearrangement
Chr t(4;11)(q21;q23)
TS 12
Chr t(5;7;7)(q33.2;q32;q11.2)
Chr t(9;11)
Chr t(14;21)(q22;q22)
Chr t(4;9;22)(q21;q34;q11.2)
Chr del(17p) + Chr del(11q)
Chr del(13)(q14)
BCL2L1 overexpression
MYC overexpression + IDH2 mutation
MYC overexpression + IDH1 mutation
IKZF1 deletion + CDKN2A deletion
IKZF1 deletion + CDKN2B deletion
CD28 overexpression
PTEN underexpression
miR-543 overexpression
miR-494 overexpression
miR-495 overexpression
TNFRSF13C expression
CIP2A elevation
NRAS mutation + U2AF1 mutation
PIM2 overexpression
NFKB1 overexpression
DCK exon 6 mutation
DCK exon 4 mutation
Chr del(11q) + ATM mutation
ATM mutation + IGH mutation
PAX5-JAK2 fusion
Chr t(14;16)
ABCC2 3972C>T
POT1 mutation
ARNT expression
INPP4B overexpression
MLL translocation
Chr del(8p)
ID3 underexpression
BCL2 G101V + SF3B1 mutation
NOTCH1 mutation
ZMYM2-FGFR1 fusion
EIF2A mutation + Chr del(8p)
IGLV3 21R110
MLL2 mutation + Chr del(8p)
EP300 mutation + Chr del(8p)
Chr t(15;17)/PML-RARA fusion
ATM mutation
KDM6A mutation
SNX2-ABL1 fusion
BCL2L2 overexpression
Chr t(3;5)(q25;q35)
BTK C481S + PLCG2 L845F
BTK C481S + PLCG2 D1140G
STAT5B N642H
TCL1A rearrangement
RAD50 Y625
ATM D2721N
BTK C481S + PLCG2 D1140N
ITGA4 overexpression
HGF-L
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
NPM1 mutation + NRAS mutation
CCND3 T283A
CCND3 Q276* + CCND3 S264R
FGFR1 rearrangement + Chr t(8;13)
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
PTBP1 overexpression
MEF2C overexpression
Chr t(11;14)
MLL fusion
NFE2L2 overexpression
TCF3-EPAS1 fusion
SIRT3 expression
AKT2 expression
MCL1 overexpression
ATP6AP2 overexpression
CTSA overexpression
IGF2R overexpression
KDM4D mutation
ITGAM expression
GFI1 36N
PD-L2 overexpression
CD9 expression
miR-155 deletion + FLT3-ITD mutation
IDH2 mutation + NRAS mutation
MLL-PTD
FOXO1 underexpression
HER-2 expression
FASN-L
PAK2 overexpression
LPL deletion + TP53 deletion
CD70 expression
CXCL13 elevation
Chr del(17)(p13)
B2M elevation
MYC-IGH fusion
CCL22 underexpression
TGFA overexpression
CCL11 overexpression
DDB2 rs830083
CD33 expression + CD7 expression
BCR-FGFR1 fusion
CXCL10 elevation
CCL2 overexpression
IL1A elevation
LY9 expression
CBL C384Y
KDM6B overexpression + TET2 deletion
ETV6-ABL1 fusion
SSBP2-CSF1R fusion
RCSD1-ABL2 fusion
FLT3 mutation + NRAS mutation
NF1 deletion
RASGRP1 overexpression
IGH-CRLF2 fusion + JAK2 R867Q
JAK1 S646F
IGH-CRLF2 fusion + JAK2 R683G
IGH-CRLF2 fusion
IGH-CRLF2 fusion + JAK2 GPInsR683
P2RY8-CRLF2 fusion + JAK2 QGinsR683
NOTCH1 expression
Chr rearrangement(11)(q23)
GADD45A overexpression + BCL2L10 overexpression + PMAIP1 overexpression
FLT3-ITD mutation + NRAS mutation + GATA2 mutation
AR underexpression + IL1R1 underexpression + CCND1 overexpression
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression
MSLN overexpression
HAVCR2 expression
TNFRSF4 expression
EPHB2 overexpression + FLT3-ITD mutation
CSK overexpression + FLT3-ITD mutation
HCK overexpression + FLT3-ITD mutation
LYN overexpression + FLT3-ITD mutation
Chr del(7q)
IKZF1 deletion + VPREB1 deletion
FGFR1OP2-FGFR1 fusion
GATA2 mutation
SETBP1 mutation + NRAS mutation
MCL1 underexpression
Chr amplification(11)(q23)
JAK1 S646F
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation
DNMT3A mutation + ASXL1 mutation + NRAS mutation
DNMT3A mutation + NRAS mutation
DNMT3A mutation + ASXL1 mutation
ASXL1 mutation + NRAS mutation
PRKCH overexpression
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation
FLT3-ITD mutation + ASXL1 mutation
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation
TAp63 overexpression
CBL mutation
PRPS1 A190T
PRPS1 S103T
MAFB expression
LRP1 expression
CCND3 deletion
MEF2D-CSF1R fusion
BCR-JAK2 fusion
MYB-TYK2 fusion
BAX expression
BCL2L1 underexpression
GATA1 overexpression
Chr t(8;21)(q22;q22)
AGGF1-PDGFRB fusion
PRC2 mutation
PCDHB15 overexpression
MCL1 S159A
TCRB-LCK translocation
ZBTB16-RARA fusion
NPM-RARA fusion
BRCA1 expression
BRCA2 expression
GSPT1 deletion
ATM deletion + SF3B1 mutation
KMT2D mutation
NT5C2 K359Q
NT5C2 R238W
IL22 overexpression
NT5C2 D407A
RPL10 R98S
NT5C2 R367Q
NT5C2 mutation
ROR1 positive
FAS overexpression
TNFRSF1B overexpression
TNFSF10 overexpression
MLL-AFF1 fusion + KRAS mutation
MLL-AFF1 fusion + NRAS mutation
MLL-MLLT3 fusion
CD276 expression
CD34 positive
CD34 positive + MN1 overexpression + MCL1 elevation
CD34 positive + BMI1 overexpression + MAP2K1 elevation
CBFA2T3 - GLIS2 fusion
MAP2K1 overexpression
ROR1 expression
HK2 overexpression
MCL1 expression
ANXA1 overexpression
KDM1A overexpression
ITGA4 negative
HOXA11 overexpression
BST1 positive
CD69 overexpression
CD38 expression
STAT5B-BAG1 fusion
NUP98-KDM5A fusion
NUP98-NSD1 fusion
TRAF1 overexpression
GOLGA4-JAK2 fusion
DNMT3B overexpression
MLL mutation
HMGA1 deletion+ JAK2 V617F
RNF31 deletion
WNT5A expression
FOLR1 expression
TPBG expression
RXRA overexpression
ZEB2-JAK2 fusion
ATF7IP-JAK2 fusion
HLA-A*02:01
MDM2 overexpression
KEAP1 expression
NFE2L2 expression
KMT2A rearrangement + RAS mutation
MERTK expression
PTPRC expression
SLC1A5 underexpression
SLC1A5 overexpression
AKR1C3 overexpression
PTPRC positive + KMT2A rearrangement
PTPRC positive
FCGR1A positive
MLL-AF4 fusion
PDE3A overexpression
STAT5A mutation
CD22 underexpression + BCL2 overexpression